Article: Inspire Pharmaceuticals Announces Collaboration With Cystic Fibrosis Foundation Therapeutics.

Also Presents Phase I/II Results and Receives Fast Track Designation for INS37217 Respiratory for Cystic Fibrosis

Inspire Pharmaceuticals, Inc. today announced a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a non-profit drug development affiliate of the Cystic Fibrosis Foundation, that will provide funding of a Phase II study for INS37217 Respiratory for the treatment of cystic fibrosis (CF). The Phase II study is being conducted based on results from a recently completed Phase I/II study. These results will be presented at the 16th Annual North American Cystic Fibrosis Conference, October 3-6 in New Orleans. In addition, Inspire ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!